BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
17 Diciembre 2021 - 8:30AM
Business Wire
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or
“BELLUS Health”) announced today that it has completed its
previously-announced underwritten public offering in Canada and the
United States (the “Offering”) of 25,000,000 common shares at a
price to the public of US$8.00 per common share. The total gross
proceeds to the Company were US$200 million, before deducting the
underwriting commissions and any expenses related to the Offering.
Bellus has also granted to the underwriters an option exercisable
by the underwriters within 30 days of the date of the underwriting
agreement to purchase up to an additional 3,750,000 common shares
of the Company.
BELLUS Health’s common shares are dual-listed on the Nasdaq
Global Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”)
under the trading symbol “BLU”. For the purposes of the TSX
approval, the Company relied on the exemption set forth in Section
602.1 of the TSX Company Manual, which provides that the TSX will
not apply its standards to certain transactions involving eligible
interlisted issuers on a recognized exchange, such as Nasdaq
(evidence that the volume of trading of the Company’s securities on
all Canadian marketplaces in the 12 months immediately preceding
the date of the application was less than 25% attached).
The Company intends to use the net proceeds of the Offering
primarily to fund research and development activities, general and
administrative expenses, working capital needs and other general
corporate purposes, as set out in the Supplement (as defined
below).
Jefferies, Evercore ISI and RBC Capital Markets acted as joint
book-running managers, LifeSci Capital acted as lead manager, and
H.C. Wainwright & Co. and Bloom Burton acted as
co-managers.
The Offering was made in Canada pursuant to a prospectus
supplement dated December 14, 2021 (the “Supplement”) to the
Company’s amended and restated short form base shelf prospectus
dated December 14, 2021 (the “A&R Base Prospectus”) and in the
United States pursuant to a registration statement on Form F-10,
which went effective automatically upon its filing with the U.S.
Securities and Exchange Commission (the “SEC”) on December 14, 2021
(the “Registration Statement”), containing the Supplement and
A&R Base Prospectus filed with the SEC in accordance with the
Multijurisdictional Disclosure System established between Canada
and the United States.
The Supplement and the accompanying A&R Base Prospectus
contain important detailed information about the Offering. The
Supplement and the accompanying A&R Base Prospectus can be
found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies
of the Supplement and accompanying A&R Base Prospectus may also
be obtained from the Company, by telephone at 450-680-4500 or by
email at info@bellushealth.com, or you may request them from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
877-821-7388 or by email at prospectus_department@jefferies.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, NY 10055, by telephone at
888-474-0200 or by email at ecm.prospectus@evercore.com; or RBC
Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey
Street, 8th Floor, New York, New York 10281, by telephone at (877)
822-4089 or by email at equityprospectus@rbccm.com.
No regulatory authority has either approved or disapproved the
contents of this news release. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any province,
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under
the securities laws of any such province, state or
jurisdiction.
About BELLUS Health
BELLUS Health Inc. is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of refractory
chronic cough (“RCC”) and other hypersensitization-related
disorders. The Company's product candidate, BLU-5937, is being
developed for the treatment of adults with RCC.
Cautionary Note Regarding Forward-‐Looking
Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations, the
U.S. Private Securities Litigation Reform Act of 1995, as amended,
and other applicable securities laws. Such statements, based as
they are on the current expectations of management, inherently
involve numerous important risks, uncertainties and assumptions,
known and unknown. In this news release, such forward-looking
statements include, but are not limited to, the anticipated use of
proceeds from the Offering. Actual future events may differ from
the anticipated events expressed in such forward-looking
statements. BELLUS Health believes that expectations represented by
forward-looking statements are reasonable, yet there can be no
assurance that such expectations will prove to be correct. The
reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These
forward-looking statements speak only as of the date made, and
BELLUS Health is under no obligation and disavows any intention to
update publicly or revise such statements as a result of any new
information, future event, circumstances or otherwise, unless
required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211216006254/en/
FOR MORE INFORMATION:
Investors: Ramzi Benamar Chief Financial Officer
rbenamar@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
BELLUS Health (TSX:BLU)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024